好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comparative Efficacy of Procedural vs. Medical Interventions in the Management of Free-floating Thrombus: A Systematic Review and Meta-analysis
Cerebrovascular Disease and Interventional Neurology
P7 - Poster Session 7 (11:45 AM-12:45 PM)
5-002

This systematic review and meta-analysis seeks to assess and update the existing literature on FFT management strategies and their corresponding outcomes. It also provides an insight into the sociodemographic distribution and morbidity associated with FFT.

Free floating thrombus (FFT) is a rare clinical condition with the potential risk of embolization, leading to acute ischemic stroke or transient ischemic attack. The optimal management for FFT remains uncertain.

We searched PubMed and EMBASE databases for references reporting FFT in the anterior or posterior circulation. We estimated the frequency of stroke/TIA recurrence and mortality for each treatment group. A proportion meta-analysis was performed on complete revascularization data for both groups. Complication rates were also evaluated for each group.

Our search identified 11 eligible studies encompassing a total of 243 patients. The mortality rates for the medical and procedural intervention groups were 3.80% and 6.52% respectively. Post-treatment recurrence rates of stroke/TIA were 9.52% for the medical intervention and 0.72% for the procedural intervention group. The estimated pooled complete revascularization rates stood at 35.4% (95% CI: 17.5% to 55.2%) for the medical group and 72.4% (95% CI: 62.5% to 81.5%) for the procedural group. Complication rates were 17% for the medical intervention group, and 28% for the procedural intervention group.

In managing FFT patients, procedural intervention offers higher revascularization rates potentially reducing stroke recurrence but carries greater mortality and complication risks compared to medical treatment. Robust, extended-duration research, particularly randomized controlled trials (RCTs), are essential for generating more reliable outcomes. 

Authors/Disclosures
Fairoz Jayyusi
PRESENTER
Miss Jayyusi has nothing to disclose.
Shahed Aljabeiti (Jordan University of Science and Technology) No disclosure on file
Mohammad Jehad J. Taha Dr. Taha has nothing to disclose.
Sabren Badir No disclosure on file
Mohmmad M. Alawajneh (Jordan University of Science and Technology) Mr. Alawajneh has nothing to disclose.
Aiman A. Momani, MD, PhD Dr. Momani has nothing to disclose.
Amro Hasan (Jordan University of Science and Technology) No disclosure on file
Mustafa Abuelsamen No disclosure on file
Mays A. Shawawrah IV, MD (Kingston Health Sciences Centre) Dr. Shawawrah has nothing to disclose.